MyMD Pharmaceuticals, Inc. entered into a Securities Purchase Agreement to sell shares of Series G Convertible Preferred Stock and warrants to purchase common stock, and made amendments to increase the number of authorized shares of Preferred Stock. Christopher Chapman resigned as President and Chief Medical Officer, and Stephen Friscia was appointed as a new board member. Mitchell Glass was appointed as President and Chief Medical Officer. A press release was issued announcing the appointments.